[go: up one dir, main page]

MX2009003360A - Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina. - Google Patents

Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina.

Info

Publication number
MX2009003360A
MX2009003360A MX2009003360A MX2009003360A MX2009003360A MX 2009003360 A MX2009003360 A MX 2009003360A MX 2009003360 A MX2009003360 A MX 2009003360A MX 2009003360 A MX2009003360 A MX 2009003360A MX 2009003360 A MX2009003360 A MX 2009003360A
Authority
MX
Mexico
Prior art keywords
rapidly disintegrating
receptor antagonist
thrombin receptor
oral formulations
lyophilized oral
Prior art date
Application number
MX2009003360A
Other languages
English (en)
Inventor
Enrico P Veltri
Anastasia Pavlovsky
David Monteith
Suliman Chawdry
Srinivas Duggirala
Michael Angelo Falvo
John R Ii Erbey
Kung-I Feng
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009003360A publication Critical patent/MX2009003360A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una forma de dosificación sólida de rápida desintegración liofilizada, una modalidad de la cual comprende un antagonista del receptor de trombina tal como, (ver fórmula (A)) o su sal o hidrato aceptable para uso farmacéutico, un polímero tal como gelatina, y un agente formador de matriz tal como manitol; los sistemas reguladores de pH eficaz de la suspensión liofilizada previamente se enseñan, junto con los métodos para tratar pacientes en riesgo de contraer el síndrome coronario agudo administrando ese tipo de forma de dosificación sólida de desintegración rápida.
MX2009003360A 2006-09-26 2007-09-24 Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina. MX2009003360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84730606P 2006-09-26 2006-09-26
PCT/US2007/020569 WO2008039406A2 (en) 2006-09-26 2007-09-24 Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist

Publications (1)

Publication Number Publication Date
MX2009003360A true MX2009003360A (es) 2009-04-14

Family

ID=39230776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003360A MX2009003360A (es) 2006-09-26 2007-09-24 Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina.

Country Status (16)

Country Link
US (1) US20080152712A1 (es)
EP (1) EP2068823A2 (es)
JP (1) JP2010504911A (es)
KR (1) KR20090057400A (es)
CN (1) CN101541302A (es)
AR (1) AR062979A1 (es)
AU (1) AU2007300517A1 (es)
CA (1) CA2664290A1 (es)
CL (1) CL2007002759A1 (es)
CO (1) CO6170417A2 (es)
MX (1) MX2009003360A (es)
NO (1) NO20091644L (es)
PE (1) PE20080673A1 (es)
TW (1) TWI343262B (es)
WO (1) WO2008039406A2 (es)
ZA (1) ZA200902592B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
MX2009006873A (es) * 2006-12-22 2009-07-03 Schering Corp Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.
EP2358366A1 (en) * 2008-11-17 2011-08-24 Schering Corporation Pharmacokinetically-based dosing regimens of a thrombin receptor antagonist
DK2438060T3 (da) 2009-06-04 2014-01-13 Merck Sharp & Dohme Aktiv metabolit af en trombin-receptor-antagonist
CA2764172A1 (en) 2009-06-08 2010-12-16 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
US10744086B2 (en) * 2009-10-30 2020-08-18 Ix Biopharma Ltd. Fast dissolving solid dosage form
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
WO2017134200A1 (en) 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
EP4243796A4 (en) * 2020-11-16 2025-01-22 Orcosa Inc. IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
JPH07116022B2 (ja) * 1989-04-18 1995-12-13 三共株式会社 凍結乾燥製剤の製法
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
CA2392810A1 (en) * 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
CN103356996A (zh) * 2000-05-19 2013-10-23 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
MXPA02012447A (es) * 2000-06-15 2003-04-25 Schering Corp Antagonistas receptores de trombina.
JP2005500253A (ja) * 2001-02-23 2005-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物
MEP13408A (en) * 2001-05-29 2010-06-10 Bayer Schering Pharma Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
AR036832A1 (es) * 2001-10-18 2004-10-06 Schering Corp Compuestos derivados de himbacina, agonistas receptores de trombina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos
PT1495018E (pt) * 2002-04-16 2008-02-19 Schering Corp Antagonistas tricíclicos de receptores de trombina
JP2009521472A (ja) * 2005-12-22 2009-06-04 シェーリング コーポレイション 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist

Also Published As

Publication number Publication date
PE20080673A1 (es) 2008-06-14
TWI343262B (en) 2011-06-11
US20080152712A1 (en) 2008-06-26
ZA200902592B (en) 2010-03-31
CO6170417A2 (es) 2010-06-18
CA2664290A1 (en) 2008-04-03
EP2068823A2 (en) 2009-06-17
CL2007002759A1 (es) 2008-03-24
KR20090057400A (ko) 2009-06-05
JP2010504911A (ja) 2010-02-18
NO20091644L (no) 2009-04-24
CN101541302A (zh) 2009-09-23
TW200820995A (en) 2008-05-16
AU2007300517A1 (en) 2008-04-03
WO2008039406A3 (en) 2008-07-03
WO2008039406A2 (en) 2008-04-03
AR062979A1 (es) 2008-12-17

Similar Documents

Publication Publication Date Title
MX2009003360A (es) Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina.
CY1126116T1 (el) Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
WO2007048219A3 (en) Sustained drug release composition
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
NO20076418L (no) Heterocyclic compounds as agonists for the thyroid receptor
CY1118227T1 (el) Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
NO20090593L (no) Modulatorer av farmakokinetikkegenskaper til terapeutika
MX2010003923A (es) Formulacion farmaceutica de valsartan.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MY162319A (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
UA102120C2 (ru) Пероральная форма дозирования бендамустина
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
PH12013500173A1 (en) Oral controlled release pharmaceutical compositions of blonanserin
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2008005352A3 (en) Solid dose formulations of a thrombin receptor antagonist

Legal Events

Date Code Title Description
FA Abandonment or withdrawal